177 related articles for article (PubMed ID: 32876657)
21. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
23. Open-label study of etanercept treatment in patients with moderate-to-severe plaque psoriasis who lost a satisfactory response to adalimumab.
Bagel J; Tyring S; Rice KC; Collier DH; Kricorian G; Chung J; Iles J; Stolshek BS; Kaliyaperumal A; Papp KA
Br J Dermatol; 2017 Aug; 177(2):411-418. PubMed ID: 28196270
[TBL] [Abstract][Full Text] [Related]
24. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation.
Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Giuliano A; Sabato S; Stramazzotti D; Gulini E; Dusi D; De Blasio S; Fabris G; Offidani A
Int J Immunopathol Pharmacol; 2009; 22(2):371-7. PubMed ID: 19505391
[TBL] [Abstract][Full Text] [Related]
25. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
[TBL] [Abstract][Full Text] [Related]
26. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
[TBL] [Abstract][Full Text] [Related]
27. Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis: A Step Toward Personalized Treatment.
Menting SP; Coussens E; Pouw MF; van den Reek JM; Temmerman L; Boonen H; de Jong EM; Spuls PI; Lambert J
JAMA Dermatol; 2015 Jun; 151(6):616-22. PubMed ID: 25807311
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.
Zweegers J; Groenewoud JMM; van den Reek JMPA; Otero ME; van de Kerkhof PCM; Driessen RJB; van Lümig PPM; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Arnold WP; Andriessen MPM; Kuijpers ALA; Berends MAM; Kievit W; de Jong EMGJ
Br J Dermatol; 2017 Apr; 176(4):1001-1009. PubMed ID: 27579864
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
Armstrong AW; Betts KA; Sundaram M; Thomason D; Signorovitch JE
J Am Acad Dermatol; 2016 Oct; 75(4):740-746. PubMed ID: 27476973
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
Papp KA; Yang M; Sundaram M; Jarvis J; Betts KA; Bao Y; Signorovitch JE
Value Health; 2018 Jan; 21(1):1-8. PubMed ID: 29304933
[TBL] [Abstract][Full Text] [Related]
31. Landscape of Long Noncoding RNAs in Psoriatic and Healthy Skin.
Gupta R; Ahn R; Lai K; Mullins E; Debbaneh M; Dimon M; Arron S; Liao W
J Invest Dermatol; 2016 Mar; 136(3):603-609. PubMed ID: 27015450
[TBL] [Abstract][Full Text] [Related]
32. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
33. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
[TBL] [Abstract][Full Text] [Related]
34. Cytokine responses in nonlesional psoriatic skin as clinical predictor to anti-TNF agents.
Tsoi LC; Patrick MT; Shuai S; Sarkar MK; Chi S; Ruffino B; Billi AC; Xing X; Uppala R; Zang C; Fullmer J; He Z; Maverakis E; Mehta NN; Perez White BE; Getsios S; Helfrich Y; Voorhees JJ; Kahlenberg JM; Weidinger S; Gudjonsson JE
J Allergy Clin Immunol; 2022 Feb; 149(2):640-649.e5. PubMed ID: 34343561
[TBL] [Abstract][Full Text] [Related]
35. Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.
Papp KA; Armstrong AW; Reich K; Karunaratne M; Valdecantos W
Am J Clin Dermatol; 2016 Feb; 17(1):79-86. PubMed ID: 26547918
[TBL] [Abstract][Full Text] [Related]
36. Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin.
D'Amico F; Trovato C; Skarmoutsou E; Rossi GA; Granata M; Longo V; Gangemi P; Pettinato M; Mazzarino MC
J Dermatol Sci; 2015 Oct; 80(1):38-44. PubMed ID: 26276441
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
38. A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis.
Núñez M; Huete T; de la Cueva P; Sacristán JA; Hartz S; Dilla T
Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):546-553. PubMed ID: 30851873
[TBL] [Abstract][Full Text] [Related]
39. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
40. IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab.
Gedebjerg A; Johansen C; Kragballe K; Iversen L
Acta Derm Venereol; 2013 Mar; 93(2):150-5. PubMed ID: 22930279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
